Problem: Optimal lung cancer care requires multidisciplinary team input, with access to specialised diagnostic and therapeutic services that may be limited in rural or regional areas and impact clinical outcomes. Clinical quality indicators can be used to measure the quality of care delivered to patients with lung cancer in a region and identify areas for improvement. We describe the implementation of internationally recognised clinical quality indicators for lung cancer care in the Barwon South Western region.
Design: The consensus of an expert panel was used for the selection of clinical quality indicators. The data were retrospectively collected from the Evaluation of Cancer Outcomes Barwon South West Registry, which systematically records detailed information on all new patients with cancer in the region.
Setting: Region-based health service.
Key Measures For Improvement: Adherence to clinical quality indicator targets.
Strategies For Change: Clinical quality indicators, which fall short of the expected targets, highlight areas for improvement in the service provided to patients with lung cancer. These results have prompted changes in the service offered to these patients, such as the introduction of a multidisciplinary lung cancer clinic.
Effects Of Change: The multidisciplinary lung cancer clinic has streamlined the access to lung cancer services, including specialist consultations, diagnostics and therapeutic services, in a regional setting. Ongoing data collection is required to determine the effect of such changes on adherence to clinical quality indicator targets.
Lessons Learnt: The regular monitoring of clinical quality indicators serves as a useful method of quality assurance in the care of patients with lung cancer. We expect these clinical quality indicators to also be used by other health services to analyse and improve services provided to patients with lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajr.12493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research progress on the association between lung cancer and pulmonary embolism.
J Cardiothorac Surg
January 2025
Department of Respiratory Medicine, Anhui Medical University Clinical College of Chest & Anhui Chest Hospital, Hefei, 230022, People's Republic of China.
Pulmonary embolism (PE), a form of venous thromboembolism, is a frequently observed complication in malignancies, with a notably high incidence in individuals with lung cancer. The presence of PE markedly reduces the quality of life and has a significant impact on the prognosis of those diagnosed with both lung cancer and PE. As a result, timely diagnosis and intervention are of paramount importance.
View Article and Find Full Text PDFEvaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.
BMC Cancer
January 2025
Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Objective: Rapid on-site evaluation (ROSE) of respiratory cytology specimens is a critical technique for accurate and timely diagnosis of lung cancer. However, in China, limited familiarity with the Diff-Quik staining method and a shortage of trained cytopathologists hamper utilization of ROSE. Therefore, developing an improved deep learning model to assist clinicians in promptly and accurately evaluating Diff-Quik stained cytology samples during ROSE has important clinical value.
View Article and Find Full Text PDFPreoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I-IIIB small-cell lung cancer.
BMC Cancer
January 2025
Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Background: To date, there remains a paucity of comparative investigations pertaining to preoperative immunochemotherapy and conventional chemotherapy in the context of limited-stage small-cell lung cancer (LS-SCLC) patients. This study conducted a comprehensive comparative assessment concerning the safety and efficacy profiles of preoperative immunochemotherapy and chemotherapy in individuals diagnosed with stage I-IIIB SCLC.
Methods: This investigation collected 53 consecutive patients diagnosed with LS-SCLC spanning stage I to IIIB who underwent preoperative immunochemotherapy or conventional chemotherapy at our hospital from January 2019 to July 2021.
Mucormycosis Infection in Lung Transplant Patients: Experience in Andalusia, Spain.
Transplant Proc
January 2025
Department of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba, IMIBIC, University of Córdoba, Córdoba, Spain; Group for the Study of Thoracic Neoplasms and Lung Transplantation, IMIBIC (Instituto Maimónides de Investigación Biomédica de Córdoba), University of Córdoba, Córdoba, Spain. Electronic address:
Introduction: Mucorales infections in the airways of lung transplant (LT) patients are rare but have a rising incidence in transplanted lungs.
Objective: We present our experience with LT in immediate postoperative infections due to mucormycosis.
Methods: Review of 767 LT performed in Andalusia between 2000 and 2023 identifying Mucorales through microbiological results and histological findings.
Screening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN) II.
Can J Surg
January 2025
From the Faculty of Medicine, Dalhousie University, Halifax, N.S. (Huo); the Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece (Kontouli); the Department of Diagnostic Radiology, Dalhousie University, Halifax, N.S. (Manos); the Department of Pathology, Dalhousie University, Halifax, N.S. (Xu, Fris); the Department of Urology, Dalhousie University, Halifax, N.S. (Chun); the Division of Thoracic Surgery, Department of Surgery, Dalhousie University, Halifax, N.S. (Wallace, French)
Background: There is a need to expand eligibility criteria for lung cancer screening beyond age and smoking history. In this study, we sought to assess whether light-or-never-smokers and heavy smokers differ in molecular and immunologic markers based on conventional lung cancer screening criteria.
Methods: We conducted a retrospective review of lung cancer cases from 2005 to 2018 at a tertiary Canadian institution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!